Real Endpoints Thought-Leadership in Action

Oct 11-12: The Alliance for Innovation in Integrated Healthcare

Jeff Berkowitz, CEO

Jeff Berkowitz participated in a panel discussion at AIIH focused on driving the transition to value-based care. The panel was moderated by Scott Ransom from Oliver Wyman and was a robust discussion on the realities and hopes related to value-based care including issues related to data, capabilities, technology and provider support.

Jane Barlow, Chief Clinical Officer

At the inaugural AIIH summit, Dr Barlow participated in a panel discussion around durable cell and gene therapies with a focus on innovative contracting to facilitate access and coverage.

October 13-14: Association for Value-Based Cancer Care

Roger Longman, Founder & Chairman

Roger Longman keynoted the AVBCC conference with an analysis of how oncology has resisted payer management — and what’s changing the traditional calculus, including the first real value-based agreements. He then led a contentious panel discussion on the topic, with top execs from payers, pharmas, and provider groups.

Susan Raiola, President

Susan Raiola took part in the Patient Centricity & Connectivity in Oncology Support Services Panel. Susan’s remarks focused on what makes a good oncology support program as well as on what oncologists and life science companies need to learn from patients, consumers, and care partners to better address their unmet needs.

Jane Barlow, Chief Clinical Officer

Jane Barlow moderated a panel centering around the viability of VBAs in oncology. Throughout the discussion, she probed panelists on the success or failure of existing oncology VBAs and what could make them more successful. As context, she highlighted the MIT FoCUS project’s work on precision financing solutions related to curative gene/cell therapies for sustainable patient access.

Rob O’Brien, VP, Specialty

Don’t forget about us…the voice of the regional health plan and self-insured employer. The panelists provided insights and perspective on their unique challenges and ideas for innovation when it comes to managing oncology and the opportunity to partner with manufacturers and prescribers on more value-based contracting strategies.

Jeff Berkowitz, CEO

Jeff Berkowitz moderated a provocative panel that concentrated on the legal and regulatory issues impacting value-based care agreements. Along with Ariane Horn, JD (Partner, Arnold & Porter), Jeff provided clarity on legal and regulatory issues that may inhibit value-based contracting in oncology currently and discussed regulatory changes that will create a better environment for value-based agreements.

Jane Barlow, Chief Clinical Officer

Jane Barlow moderated a thought provoking panel focused on value-based agreements that exist outside of oncology. The panelists discussed existing VBAs for non-oncology products, facilitators and barriers to these deals, and best practices for successfully adopting these learnings to the oncology setting.

Oct 18-19: AMCP Nexus

Rob O’Brien took part in the Prescription Digital Therapeutics Round Table, an active discussion on defining what these new drugs are and what’s promising and problematic about them.

Meanwhile, Jane Barlow presented MIT FoCUS survey data on emerging market solutions to address the coverage and reimbursement challenges associated with durable cell and gene therapy.

Rob O’Brien, VP, Specialty

Jane Barlow, Chief Clinical Officer

Oct 26-29: Asembia Summit

Jeff Berkowitz was a panelist on “The State of Value Based Contracting” – an engaging discussion around the essentials of such agreements, how to optimally integrate them, and future considerations for the pharmaceutical marketplace.

Jeff Berkowitz, CEO